Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Aggarwal RR, Ryan CJ, Chan JM.

Urol Oncol. 2013 Jul;31(5):522-30. doi: 10.1016/j.urolonc.2011.05.001. Epub 2011 Jun 12. Review.

PMID:
21658978
2.

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR.

J Clin Endocrinol Metab. 2013 May;98(5):E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26.

3.

Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.

Hara N, Takizawa I, Isahaya E, Nishiyama T, Hoshii T, Ishizaki F, Takahashi K.

Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.

PMID:
21458314
4.

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Karantanos T, Corn PG, Thompson TC.

Oncogene. 2013 Dec 5;32(49):5501-11. doi: 10.1038/onc.2013.206. Epub 2013 Jun 10. Review.

5.

Reconsideration of progression to CRPC during androgen deprivation therapy.

Mizokami A, Namiki M.

J Steroid Biochem Mol Biol. 2015 Jan;145:164-71. doi: 10.1016/j.jsbmb.2014.03.015. Epub 2014 Apr 6. Review.

PMID:
24717975
6.

SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.

Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Itsumi M, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Eur J Cancer. 2015 Sep;51(14):1962-9. doi: 10.1016/j.ejca.2015.06.122. Epub 2015 Jul 11.

PMID:
26169017
8.

Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.

Hara N, Ishizaki F, Saito T, Nishiyama T, Kawasaki T, Takahashi K.

Urology. 2013 Feb;81(2):376-80. doi: 10.1016/j.urology.2012.10.050.

PMID:
23374809
9.

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration.

Fraga A, Ribeiro R, Príncipe P, Lobato C, Pina F, Maurício J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R.

Eur J Cancer. 2014 Jan;50(2):359-65. doi: 10.1016/j.ejca.2013.09.001. Epub 2013 Sep 30.

PMID:
24090974
11.

Implications of insulin-like growth factor-I for prostate cancer therapies.

Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y.

Int J Urol. 2009 Feb;16(2):161-7. doi: 10.1111/j.1442-2042.2008.02224.x. Epub 2008 Dec 5. Review.

12.

Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.

Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K.

Urology. 2010 Jun;75(6):1441-5. doi: 10.1016/j.urology.2009.11.021. Epub 2010 Jan 29.

PMID:
20110105
13.

Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A.

Cancer Res. 2005 Mar 1;65(5):1849-57.

14.

Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.

Ishizaki F, Hara N, Takizawa I, Nishiyama T, Isahaya E, Kawasaki T, Takahashi K.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):122-8. doi: 10.1016/j.ghir.2012.04.003. Epub 2012 May 11.

PMID:
22579549
15.

Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.

Katzenwadel A, Wolf P.

Cancer Lett. 2015 Oct 10;367(1):12-7. doi: 10.1016/j.canlet.2015.06.021. Epub 2015 Jul 13. Review.

16.

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.

Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K.

Prostate. 2010 Feb 1;70(2):155-61. doi: 10.1002/pros.21047.

PMID:
19760629
17.

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.

Cancer Res. 2004 Dec 1;64(23):8620-9.

18.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
19.
20.

Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.

Brungs D, Chen J, Masson P, Epstein RJ.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):105-11. doi: 10.1038/pcan.2014.10. Epub 2014 Apr 1. Review.

PMID:
24686773
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk